


Figure 1



Sequences 1-40 (some did not sequence) panning 3 expt 1

His Thr Thr Val Tyr Gly Ala Gly
CAT ACG ACT GTT TAT GGG GCT GGT

Thr Glu Thr Pro Tyr Pro Thr Gly
ACT GAG ACG CCT TAT CCT ACT GGT

Leu Thr Thr Pro Phe Ser Ser Gly
CTT ACT ACT CCG TTT TCG TCG GGT

Gly Val Pro Leu Thr Met Asp Gly
GGT GTG CCT CTT ACG ATG GAT GGT

Lys Leu Pro Thr Val Leu Arg Gly
AAG CTT CCG ACT GTT CTG CGG GGT

Cys Arg Phe His Gly Asn Arg Gly
TGT CGC TTT CAT GGG AAT CGT GGT

Tyr Thr Arg Asp Phe Glu Ala Gly
TAT ACT CGG GAT TTT GAG GCT GGT

Ser Ser Ala Ala Gly Pro Arg Gly
TCG TCG GCG GCT GGT CCG CGG GGT

Ser Leu Ile Gln Tyr Ser Arg Gly
TCT CTG ATT CAG TAT TCG AGG GGT

Asp Ala Leu Met Trp. Pro UKN Gly
GAT GCT CTT ATG TGG CCT NTG GGT

Ser Ser UKN Ser Leu Tyr Ile Gly
TCG TCT CNT TCG TTG TAT ATT GGT

Phe Asn Thr Ser Thr Arg Thr Gly
TTT AAT ACT TCG ACG CGT ACG GGT

Thr Val Gln His Val Ala Phe Gly
ACT GTG CAG CAT GTT GCT TTT GGT

Asp Tyr Ser Phe Pro Pro Leu Gly
GAT TAT TCT TTT CCG CCT CTT GGT

Val Gly Ser Met Glu Ser Leu Gly
GTG GGG TCT ATG GAG TCG TTG GGT

Phe UKN Pro Met Ile UKN Ser Gly
TTT CAN CCG ATG ATT NGN TCG GGT

Ala Pro Pro Arg Val Thr Met Gly
GCG CCT CCG CGG GTT ACT ATG GGT

FIGURE 1H.

10053459.01302

30-26 (sheet 3 of 41)

Ile Ala Thr Lys Thr Pro Lys Gly
ATT GCT ACG AAG ACG CCT AAG GGT

Lys Pro Pro Leu Phe Gln Ile Gly
AAG CCT CCG TTG TTT CAG ATT GGT

Tyr His Thr Ala His Asn Met Gly
TAT CAT ACT GCT CAT AAT ATG GGT

Ser Tyr Ile Gln Ala Thr His Gly
TCT TAT ATT CAG GCT ACG CAT GGT

Ser Ser Phe Ala Thr Phe Leu Gly
TCG TCT TTT GCT ACT TTT CTT GGT

Thr Thr Pro Pro Asn Phe Ala Gly
ACG ACT CCG CCG AAT TTT GCG GGT

Ile Ser Leu Asp Pro Arg Met Gly
ATT TCT CTT GAT CCG CGT ATG GGT

Ser Leu Pro Leu Phe Gly Ala Gly
TCG CTG CCG CTG TTT GGT GCG GGT

Asn Leu Leu Lys Thr Thr Leu Gly
AAT CTT CTT AAG ACT ACG CTT GGT

Asp Gln Asn Leu Pro Arg Arg Gly
GAT CAG AAT CTG CCG CGG CGG GGT

Ser His Phe Glu Gln Leu Leu Gly
AGT CAT TTT GAG CAG CTG CTT GGT

Thr Pro Gln Leu His His Gly Gly
ACG CCG CAG CTT CAT CAT GGT GGT

Ala Pro Leu Asp Arg Ile Thr Gly
GCG CCT CTG GAT AGG ATT ACG GGT

Phe Ala Pro Leu Ile Ala His Gly
TTT GCG CCT CTT ATT GCG CAT GGT

Ser Trp Ile TER Thr Phe Met Gly
TCG TGG ATT TAG ACG TTT ATG GGT

Asn Thr Trp Pro His Met Tyr Gly
AAT ACT TGG CCT CAT ATG TAT GGT

Glu Pro Leu Pro Thr Thr Leu Gly
GAG CCT CTT CCG ACT ACG TTG GGT

His Gly Pro His Leu Phe Asn Gly
CAT GGG CCT CAT CTG TTT AAT GGT

1 H (cont.)

2025-10-26 10:30:00

309. 6 (sheet 4 of 11)


Tyr	Leu	Asn	Ser	Thr	Leu	Ala	Gly
TAT	CTG	AAT	TCT	ACG	CTT	GCT	GGT

His	Leu	His	Ser	Pro	Ser	Gly	Gly
CAT	CTT	CAT	AGT	CCG	TCG	GGG	GGT

204T.D. 854E300T

1 H (cont)

Figure 2



202410-8645007

30726 (sheet 6041)

Translated sequences 41-80 (not all sequenced) panning #3 expt #3

Thr Leu Pro His Arg Leu Asn Gly
ACT CTG CCT CAT CGT CTG AAT GGT

Ser Ser Pro Arg Glu Val His Gly
TCG AGT CCG AGG GAG GTT CAT GGT

Asn Gln Val Asp Thr Ala Arg Gly
AAT CAG GTT GAT ACG GCT CGG GGT

Tyr Pro Thr Pro Leu Leu Thr Gly
TAT CCT ACG CCG CTG CTG ACT GGT

His Pro Ala Ala Phe Pro Trp Gly
CAT CCT GCT GCT TTT CCT TGG GGT

Leu Leu Pro His Ser Ser Ala Gly
CTT CTT CCG CAT TCT AGT GCT GGT

Leu Glu Thr Tyr Thr Ala Ser Gly
CTT GAG ACT TAT ACG GCT TCT GGT

Lys Tyr Val Pro Leu Pro Pro Gly
AAG TAT GTG CCT CTG CCG CCG GGT

Ala Pro Leu Ala Leu His Ala Gly
GCG CCG TTG GCT CTG CAT GCG GGT

Tyr Glu Ser Leu Leu Thr Lys Gly
TAT GAG TCG CTG CTG ACT AAG GGT

Ser His Ala Ala Ser Gly Thr Gly
TCT CAT GCG GCT TCT GGT ACT GGT

Gly Leu Ala Thr Val Lys Ser Gly
GGT TTG GCG ACT GTT AAG TCT GGT

Gly Ala Thr Ser Phe Gly Leu Gly
GGT GCT ACG TCT TTT GGG CTT GGT

Lys Pro Pro Gly Pro Val Ser Gly
AAG CCG CCT GGG CCG GTG TCG GGT

Thr Leu Tyr Val Ser Gly Asn Gly
ACT CTT TAT GTT TCT GGG AAT GGT

His Ala Pro Phe Lys Ser Gln Gly
CAT GCT CCG TTT AAG TCT CAG GGT

Val Ala Phe Thr Arg Leu Pro Gly
GTG GCG TTT ACG CGG CTT CCG GGT

FIGURE 2H.

2025-01-01 10:54:50

E 3926 (sheet 7 F 41)

Leu Pro Thr Arg Thr Pro Ala Gly
CTG CCG ACT CGT ACG CCG GCT GGT

Ala Ser Phe Asp Leu Leu Ile Gly
GCG AGT TTT GAT CTT TTG ATT GGT

Arg Met Asn Thr Glu Pro Pro Gly
CGG ATG AAT ACT GAG CCT CCG GGT

Lys Met Thr Pro Leu Thr Thr Gly
AAG ATG ACT CCT CTG ACG ACT GGT

Ala Asn Ala Thr Pro Leu Leu Gly
GCG AAT GCG ACG CCT CTG CTG GGT

Thr Ile Trp Pro Pro Pro Val Gly
ACT ATT TGG CCT CCG CCT GTT GGT

Gln Thr Lys Val Met Thr Thr Gly
CAG ACT AAG GTG ATG ACG ACG GGT

Asn His Ala Val Phe Ala Ser Gly
AAT CAT GCT GTT TTT GCT AGT GGT

Leu His Ala Ala UKN Thr Ser Gly
CTG CAT GCG GCT ANT ACG TCG GGT

Thr Trp Gln Pro Tyr Phe His Gly
ACG TGG CAG CCG TAT TTT CAT GGT

Ala Pro Leu Ala Leu His Ala Gly
GCG CCG TTG GCT CTG CAT GCG GGT

Thr Ala His Asp Leu Thr Val Gly
ACG GCG CAT GAT CTG ACT GTT GGT

Asn Met Thr Asn Met Leu Thr Gly
AAT ATG ACT AAT ATG CTT ACT GGT

Gly Ser Gly Leu Ser Gln Asp Gly
GGT TCT GGG CTG TCT CAG GAT GGT

Thr Pro Ile Lys Thr Ile Tyr Gly
ACG CCG ATT AAG ACG ATT TAT GGT

Ser His Leu Tyr Arg Ser Ser Gly
TCG CAT CTG TAT CGT TCT AGT GGT

2H (cont)

2053498-01102

Figure 3A




Figure 3B




Figure 4A





Figure 4B



30926 (sheet 9 of 41)

Figure 5A





Figure 5B



30926 (sheet 10 of 41)

Figure 6A

EL4 cells pulsed with OVA peptide





Figure 6B

EL4 cells only



30926 (sheet 11 of 41.)

30926 (sheet 12 of 41)

Peptide Only Immunizations




FIGURE 7




FIGURE 8A




FIGURE 8B

GP-9960773





FIGURE 8C



D

FIGURE 8D

20211028545001

10053498.011702




FIGURE 8.




FIGURE 8F




FIGURE 8G

30926 (sheet 15 of 41)

THE AVERAGE DELAY OF ONSET OF TUMOR GROWTH




FIGURE 8(H)




FIGURE 9B

5926 (sheet 1 of 41)





FIGURE 9C.

0926 (sheet 20 of 41.)

Figure 9D.




FIGURE 10 A-B




FIGURE 10 c-d






FIGURE 10 E-F

E.







FIGURE 11 A-B

FIGURE 11C-D.

C



D





Figure 11 E-F






FIGURE 12.





FIGURE 13A

FIGURE 13.B.




37926 (sheet 2 of 4)


30926 (Sheet 30 of 41)

14A

2021081545007



Boc-Ser (O^tBu)-OH (2.5 eq.)
PyBop (2.5 eq.), DIPEA (5 eq.)
DMF, rt, 45 min




Fully Protected Peptide

FIGURE 14A

1471


(-14 to 18 f245) 9808



a) 1% TFA, CH_2Cl_2 , 2 min, rt
b) Pyridine, methanol (1: 9)
c) purification

FIGURE 14B

Figure 16A.



20270 (Sheet 3 of 4)

3: 926 (Sheet 3 of 41)




FIGURE 17A




Figure 17B.

37926 (Sheet 3 of 4)

30926 (Sheet 37 of 41)

30926-354501




Figure 17C.

3C126 (Sheet 3 of 41)





Figure 18

204710-2645001


TiterMax + OVA




Immunization 7
6/4 challenge
1x10⁶ MO4

FIGURE 19A-E


HSP70 + OVA



HSP70 + OVA-BiP



OVA alone after tumor challenge



HSP70 + OVA-BiP after tumor challenge





Figure 19 F.

Survival ratio of mice immunized 7 days before challenge with melanoma cells



36926 (sheet 40 of 41)

30.26 (sheet 41 of 41)




Figure 19G.

Figure 2